AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01485068 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Danubio paclitaxel-eluting balloon
Description: Inflation of the Danubio Paclitaxel Eluting Balloon in in-stent restenosis lesions.
Study NCT04200833 — intervention group
Intervention type: DRUG
Intervention: Golimumab
Description: subcutaneous injection
Study NCT02342873 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NS-guided interscalene block
Description: Patients received a standard single injection interscalene block using the modified lateral approach of Borgeat. The interscalene brachial plexus was identified using an insulated needle connected to a nerve stimulator. An insulated needle attached to a nerve stimulator was used to identify the brachial plexus. Placement of the needle was considered adequate if the deltoid, triceps, pectoralis, or biceps muscle motor response was still present at 0.2 - 0.5mA. Ropivacine 0.75% 20ml was used.
Study NCT02342873 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US-guided interscalene block
Description: Interscalene block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral interscalene groove visualizing the brachial plexus located between anterior and middle scalene muscles. Using in-plane technique, an insulated needle is advanced into the brachial plexus sheath, into which 20 ml of 0.75% ropivacaine is injected
Study NCT02777307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hemopatch Sealing Hemostat
Description: Place of Hemopatch Sealing Hemostat after laparoscopic cholecistectomy
Study NCT01690780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral morphine
Description: oral morphine 0.5 mg/kg (max 10 mg) every 6 hours as needed for 24 hours
Study NCT01690780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 10 mg/kg (max 600 mg) every 6 hours as needed for pain (maximum 4 doses) for 24 hours following discharge from the emergency department
Study NCT04071613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenecteplase
Description: Route: IV bolus injection Frequency: once only, within 4.5 hours of stroke onset
Study NCT04071613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous tissue plasminogen activator (tPA)
Description: Route: Intravenous (IV) infusion (10% as bolus and the remainder over 60 minutes) Frequency: once only, within 4.5 hours of stroke onset
Study NCT04306601 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Intensity Focused Ultrasound
Description: Low-intensity focused ultrasound brain stimulation using focused ultrasound system (NS-US100; NEUROSONA Co. Ltd., Seoul, Korea)
Study NCT03911206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT)
Description: IMT exercises at home will gradually ramp up
Study NCT03911206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise alone
Description: Subjects will be asked to exercise 2x/week for 6 weeks in person at the Duke research facility and again 2x/week at home for 30 minutes.
Study NCT03911206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMT and Exercise
Description: Combining IMT training and exercise
Study NCT01569113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal Acetate (UPA) + ethinylestradiol/levonorgestrel (Microgynon)
Description: UPA: 30 mg, 1 tablet, single intake Microgynon 30mcg/150mcg, 1 tablet per day, 21-day intake
Study NCT01569113 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo + ethinylestradiol/levonorgestrel
Description: placebo: 1 tablet, single intake Microgynon 30mcg/150mcg, 1 tablet per day, 21-day intake
Study NCT04220736 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Computation of quantitative flow ratio
Description: Computation of QFR was performed offline, using AngioPlus system(Pluse medical imaging technology, Shanghai, China). In the first step, 2 diagnostic angiographic projections before PCI, at least 25° apart, were selected and 3D reconstruction of the interrogated vessel without its side branches was performed. Then, the software computed the QFR.
Study NCT03214523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Education
Description: The subject will undergo a 30-minute session on sleep education from one of the study coordinators.
Study NCT04391829 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ejaculated semen sample
Description: SARS-CoV-2 positive men will be asked to give an ejaculated semen sample, within the seven days after positive testing. Semen samples will be performed every 7 days, until 2 semen PCR tests are negative and will be retested after 3 months.
Study NCT03151954 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: functional endonasal sinus surgery
Description: collect nasal polyps from patients
Study NCT03151954 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: nasal septal construction
Description: collect inferior turbinates from patients as control arm
Study NCT00844974 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Prevalence
Description: Mood and cognitive assessments
Study NCT01049282 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antigen (Ag85B-ESAT-6)
Description: Solution for injection, 0.5 mL, 50 ug antigen, 2 vaccinations with 2 months interval
Study NCT01049282 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antigen (Ag85B-ESAT-6) with adjuvant (IC31)
Description: Suspension for injection, 0.5 mL, 50 ug antigen, 2 vaccinations with 2 months interval
Study NCT03614728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3326595
Description: GSK3326595 will be administered.
Study NCT03614728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Azacitidine
Description: 5-Azacitidine will be administered.
Study NCT04411251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nature-near integrative day care unit programme
Description: Interventions based on the Mind Body Medicine in Integrative and Complementary Medicine (MICOM) programme
Study NCT04411251 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional integrative day care unit programme
Description: Interventions based on the Mind Body Medicine in Integrative and Complementary Medicine (MICOM) programme
Study NCT00903292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib (Tarceva)
Description: chemotherapy with erlotinib
Study NCT00903292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed (Alimta)
Description: Chemotherapy with pemetrexed
Study NCT01342991 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Haemorrhoidectomy
Description: The intervention comprises laser haemorrhoidectomy~This procedure will be performed under local anaesthetic with sedation as a day case~The haemorrhoids are excised using sharp dissection (over a clamp) and the cut edges are sealed using CO2 laser.~Pre-operative local anaesthesia will be given
Study NCT01342991 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Haemorrhoidectomy
Description: The intervention comprises laser haemorrhoidectomy~This procedure will be performed under local anaesthetic with sedation as a day case~The haemorrhoids are excised using sharp dissection (over a clamp) and the cut edges are sealed using CO2 laser.~Pre-operative local anaesthesia will be given
Study NCT03348527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-Hydroxyflutamide Depot
Description: Liproca® Depot is a depot formulation containing a bioresorbable, controlled-release,formulation of the nonsteroidal antiandrogen 2-hydroxyflutamide
Study NCT02305134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tipepidine Hibenzate
Study NCT02305134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04339634 — intervention group
Intervention type: OTHER
Intervention: Simulation of Repurposed Drugs for COVID-19
Description: This study is a simulation of adding repurposed drugs for COVID-19. We are using drug claims, and will not intervene with patient care.
Study NCT05016427 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VT301
Description: VT301 is off-white suspension of regulatory T cells (Tregs) (1.7x10\^5 cells/kg±15%) for injection diluted with sterile saline solution and supplied in clear, colorless, polypropylene vials.
Study NCT01933282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MESA chemotherapy
Description: Methotrexate 2g/ m2，IV d1 etoposide 100mg/ m2，VD d2，d3，d4， dexamethasone 20mg/ m2，VD d2，d3，d4, d5 Polyehylene glycol-asparaginase muscular injection 2500IU/ m2, d5
Study NCT01933282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MESA
Description: Methotrexate etoposide dexamethasone Polyehylene glycol-asparaginase
Study NCT00928057 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4mm x 32G pen needle
Description: For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were advised to inject straight in when using the 4mm PN, with no pinch up.
Study NCT00928057 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 8mm x 31G pen needle
Description: For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were directed to use pinch-up when injecting in the abdomen or thigh with the 8mm PN, and no pinch-up at other injection sites.
Study NCT00928057 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5mm x 31G pen needle
Description: For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were advised to inject straight in when using the 5mm PN, with no pinch up.
Study NCT01987128 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraneural injection
Description: BBraun Ropivacaine 1% 12ml injection divided in each sciatic components under echographic guidance with a PAJUNK SonoPlex 22G needle.
Study NCT01987128 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extraneural injection
Description: BBraun Ropivacaine 1% 12ml extraneural injection around sciatic nerve under echographic guidance with a PAJUNK SonoPlex 22G needle.
Study NCT01987128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Study NCT01987128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Study NCT01987128 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAJUNK SonoPlex 22G needle.
Study NCT01987128 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PAJUNK SonoPlex 22G needle.
Study NCT01786746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: culturally adapted cognitive behavioral therapy
Description: culturally adapted cognitive behavioral therapy for Chinese Americans. 12 sessions.
Study NCT05270382 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cetylpyridinium chloride
Description: The mouthwash is used to see the effects on wound healing and the oral microbiome.
Study NCT05270382 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: cetylpyridinium chloride
Description: The mouthwash is used to see the effects on wound healing and the oral microbiome.
Study NCT00171145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darifenacin
Description: Darifenacin 15 mg tablets once daily
Study NCT00171145 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets once daily
Study NCT04515849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cotadutide 100 micrograms
Description: Cotadutide 100 micrograms administered subcutaneously
Study NCT04515849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cotadutide 300 micrograms
Description: Cotadutide 300 micrograms administered subcutaneously
Study NCT04515849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cotadutide 600 micrograms
Description: Cotadutide 600 micrograms administered subcutaneously
Study NCT04515849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Semaglutide 1.0 miligrams administered subcutaneously
Study NCT04515849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously
Study NCT02935855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran
Study NCT02935855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Study NCT02935855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Study NCT04100070 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Monitoring of the patients
Description: Follow-up of the patients during the 12 months study periods including :~* visits with the diabetologist/pediatrician~* contacts with the service provider (nurses' visits) (more in intensive group)~* personalized monitoring of glycemic data transferred to the diabetologist/pediatrician for each visit (only in intensive group)
Study NCT02935855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Edoxaban
Study NCT02935855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Study NCT02935855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acenocumarole
Study NCT04129632 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: IEPF Wellness Tool
Description: A daily 5 minute mindfulness exercise over 28 days
Study NCT01607411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoride
Description: Fluoride Toothpaste
Study NCT01607411 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fluoride free toothpaste
Study NCT03540368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid injection
Description: Administering tranexamic acid loading dose 1 gram in 100 cc sodium chloride 0,9%, followed by maintenance dose 3 grams in infusion for 24 hours.
Study NCT03540368 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administering placebo or sodium chloride 0,9% intravenously
Study NCT04083911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine, Homoharringtonine, Aclarubicin, Cytarabine and G-CSF
Description: Decitabine:20mg/m2/d, d1\~5, intravenous infusion; Homoharringtonine:1mg/d,d3\~9,intravenous infusion; Aclarubicin:10mg/d, d3\~d6, intravenous infusion; Cytarabine:10mg/m2,q12h,d3-9, subcutaneous injection;~Granulocyte colony-stimulating factor:~50-300μg/d (when WBC counts are less than 20×10\^9/L ),subcutaneous injection;
Study NCT02502877 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam
Description: The investigators will administer 0,05mg/kg of midazolam, being 2/3 administered before the neuraxial block and 1/3 after.
Study NCT02502877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: The investigators will administer 0,033mg/kg of midazolam before the neuraxial block, and immediately after installation of the block the investigators will start a propofol TCI pump (Schnider model) with an effect concentration set at 1mcg/mL. This pump will be turned off at the end of the surgery.
Study NCT02502877 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard
Description: The investigators will administer to every patient: cefazolin 2g iv bolus, ketorolac 30 mg iv bolus, pantoprazole 40 mg iv bolus, paracetamol 1g iv perfusion (initiated 30 minutes before the end of surgery).
Study NCT02502877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: The investigators will administer to every patient: cefazolin 2g iv bolus, ketorolac 30 mg iv bolus, pantoprazole 40 mg iv bolus, paracetamol 1g iv perfusion (initiated 30 minutes before the end of surgery).
Study NCT02502877 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SpotOn
Description: Central temperature will be monitored with the SpotOnTM3MTM device from entering till leaving the operating room, through a sensor placed in the patient's forehead
Study NCT02502877 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SpotOn
Description: Central temperature will be monitored with the SpotOnTM3MTM device from entering till leaving the operating room, through a sensor placed in the patient's forehead
Study NCT02711644 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Lifestyle Counselling
Description: Each participant will meet with the intervention Registered Dietitian twice in pregnancy and have two follow-up phone calls. Participants in this group will have on-going, supportive discussions with the intervention Registered Dietitian about healthy lifestyles in pregnancy. Discussion topics with the intervention Registered Dietitian at each visit will be participant-centered, allowing the participant to guide the conversation. These conversations will be reinforced at every future contact made throughout pregnancy.
Study NCT02711644 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Lifestyle Counselling
Description: Each participant will meet in person with their respective Registered Dietitian twice in pregnancy and have two follow-up phone calls. At these visits, each participant will complete questionnaires and have anthropometric assessments (height/weight). From home, each participant will also complete online questionnaires at week 26, and week 34. Postpartum,each participant will complete an online questionnaire. Optional postpartum participation includes a focus group in the postpartum period and the option to meet with a Registered Dietitian postpartum.
Study NCT02711644 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Lifestyle Counselling
Description: Each participant will meet in person with their respective Registered Dietitian twice in pregnancy and have two follow-up phone calls. At these visits, each participant will complete questionnaires and have anthropometric assessments (height/weight). From home, each participant will also complete online questionnaires at week 26, and week 34. Postpartum,each participant will complete an online questionnaire. Optional postpartum participation includes a focus group in the postpartum period and the option to meet with a Registered Dietitian postpartum.
Study NCT00991796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-1008
Description: CS-1008 powder for concentrate for solution for infusion. six cycles of combination therapy with 3 weeks equal to one cycle. 10 mg/kg
Study NCT00991796 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00991796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel concentrate for solution for infusion. once every 3 weeks for a maximum of 6 cycles. 175 mg/m2
Study NCT00991796 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel concentrate for solution for infusion. once every 3 weeks for a maximum of 6 cycles. 175 mg/m2
Study NCT00991796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin concentrate for solution for infusion. once every 3 weeks for a maximum of 6 cycles. 6 mg/m2
Study NCT00991796 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin concentrate for solution for infusion. once every 3 weeks for a maximum of 6 cycles. 6 mg/m2
Study NCT04436419 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alpha lipoic acid (plus full hospitalization)
Description: Women are included in an 8-weeks randomized double-blind against placebo supplementation study with ALA (eight per group) according to the following criteria:~Inclusion criteria: BMI> 30; aged between 18 and 75 years. Non-inclusion criteria: HLA-DRB1\*04-03/06 polymorphisms; recent hospitalization (\<1 month); food supplement based on antioxidant; medicated in fibrate / telmisartan (modulator of PPARs); patients presenting an acute inflammatory state.~Exclusion criteria: Pregnant and/or lactating women; not affiliated with social security; not mutual health insurance; person deprived of liberty; participation in clinical research in the last 6 months.~Patients included in this clinical trial benefited from a complete hospitalization including dietary monitoring with a personalized food plan and an adapted physical activity program. α-LA (2x300mg/day of R-ALA) was administered double-blinded in the form of 2 capsules apart from meals.
Study NCT04436419 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (full hospitalization: dietary monitoring with an adapted physical activity program)
Description: Women are included in an 8-weeks randomized in placebo group. Patients included in this clinical trial benefited from a complete hospitalization including dietary monitoring with a personalized food plan and an adapted physical activity program. Placebo (2x300mg/day) was administered double-blinded in the form of 2 capsules apart from meals.